ORPHA:2157
Histidinemia
Also known as: HAL deficiency · HIS deficiency · Histidase deficiency · Histidine ammonia-lyase deficiency · Histidinuria · Hyperhistidinemia
Publications
1,061
82.5th percentile
Trials
0
Interventional, condition-specific
Researchers
1,153
Distinct authors in sample
Gene link
HAL
Moderate
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Histidinemia is a rare disorder characterized by elevated histidine levels in blood, urine, and cerebrospinal fluid, generally with no clinical repercussions.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0009345
- MeSH:C538320
- OMIM:235800
- UMLS:C0220992
Additional Mondo synonyms (6)
Hal deficiency · histidase deficiency · histidine ammonia-lyase deficiency · histidinemia · histidinuria · hyperhistidinemia
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Moderate — HAL
- LiteraturePresent
1,061 matched papers (461 in last 10 years) Source
- Phenotype characterisedPresent
39 HPO annotations (e.g. Long philtrum; Ventriculomegaly; Cerebral cortical atrophy) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Probably — there is moderate evidence for HAL.
GenCC classification: Moderate.
Phenotypes (Monarch / HPO)
39
Associated phenotypes · MONDO:0009345
- Long philtrum
- Ventriculomegaly
- Cerebral cortical atrophy
- Short middle phalanx of finger
- Rounded middle phalanx of finger
Showing 5 of 39 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,061
1,061 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,061 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
461 in the last 10 years · medium confidence · 82.5th percentile (publications denominator)
Phrase hits: 1,040 · MeSH hits: 0
Who's working on it?
1,153
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Wang Y6 papers · 2025
Key Laboratory of Geriatric Nutrition and Health, Beijing Technology and Business University, Ministry of Education, Beijing 100048, China.
Papers in Europe PMC - 02Liu X5 papers · 2025
School of Animal Science, Xinjiang Agricultural University, Urumqi, China.
Papers in Europe PMC - 03Levy HL4 papers · 2021
Division of Genetics, Children's Hospital Boston, Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
Papers in Europe PMC - 04Liu Y4 papers · 2026
Department of Forensic Pathology, School of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, China.
Papers in Europe PMC - 05Chen J3 papers · 2026
General Hospital of Northern Theater Command of China Medical University, Shenyang, Liaoning Province, P.R. China.
Papers in Europe PMC - 06Dutra-Filho CS3 papers · 2012Papers in Europe PMC
- 07Li L3 papers · 2026
NMPA Key Laboratory for Quality Control of Traditional Chinese Medicine, Shanghai Institute for Food and Drug Control, Shanghai, China.
Papers in Europe PMC - 08Li Y3 papers · 2026
Department of Neurology, Guangyuan First People's Hospital, Guangyuan, China.
Papers in Europe PMC - 09
- 10Wannmacher CM3 papers · 2012Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
medium confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 40 · after dedupe 39 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 39 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (39)
- isrctn·ISRCTN18337561·No longer recruiting·Safety and effectiveness clinical evaluation of the range of injectable HAR medical devices in facial aesthetic treatment
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12436174·No longer recruiting·Mechanism of early tissue responses in vaccination with mRNA vaccines
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN69859970·Suspended·ImMUnologiCal memOry to reSpirAtory viraL infection in the airways
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN56244307·No longer recruiting·A study to assess the safety and efficacy of a gel treatment in subjects with acne vulgaris
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN49040930·No longer recruiting·A long-term study to assess the safety and efficacy of a gel treatment in subjects with Acne Vulgaris
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13284643·No longer recruiting·Exploring Co-infection with Live Attenuated Influenza Vaccine and PneumococcuS in healthy oldEr adults (ECLIPSE)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11688703·No longer recruiting·Examining lymph node cells to assess how age affects immune responses
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN73459064·No longer recruiting·Drug interaction study with thyroid hormone and zinc preparation in healthy volunteers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17247726·No longer recruiting·Comparison of techniques of stem cell transplantation in patients with bilateral ocular surface disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17901467·Recruiting·Safety and feasibility of CD19 CAR-T cells in adults with recurrent and hard-to-treat B cell blood cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18075783·No longer recruiting·Drug interaction study with thyroid hormone and magnesium preparation in healthy volunteers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12756197·No longer recruiting·What is the inspired oxygen fraction that better predicts the need for surfactant administration for the lungs of preterm neonates with neonatal distress syndrome?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12928349·No longer recruiting·Lymph node flu and COVID-19 vaccine responses in younger or older adults
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN31763161·Stopped·A study to test the safety and immune response in adult humans of a new vaccine against four different types of Shigella bacteria
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13586698·No longer recruiting·Safety and effectiveness clinical evaluation of the range of injectable medical devices HYDRAGEL C in facial aesthetic treatment
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17936606·No longer recruiting·A study of a new vaccine against the MERS virus in adults aged 50 to 70 years
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN54869523·No longer recruiting·Study to evaluate the concentrations and safety/tolerability of IV DM199 when administered in a PVC bag
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14158719·No longer recruiting·Weight training in combination with protein supplementation in older overweight people
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16392182·No longer recruiting·Clinical study of the safety and effectiveness of the use of a hyaluronic acid injectable product (Perfectha® Finelines Lidocaine) in the treatment of wrinkles around the eyes and mouth
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN66942709·No longer recruiting·A study to assess the safety and efficacy of Poly-L-lactic acid dermal fillers in the treatment of facial ageing
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN63865080·No longer recruiting·A post-market clinical follow-up study of Perfectha Subskin Lidocaine
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN72858148·No longer recruiting·Clinical study to evaluate the safety and effectiveness of the use of two hyaluronic acid injectable products (Perfectha® Derm Lidocaine and Perfectha® Deep Lidocaine) in the treatment of lips
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN20356582·No longer recruiting·Clinical study for the safety and effectiveness of the use of Perfectha® Derm lidocaine in the treatment of medium wrinkles
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14013636·No longer recruiting·Validation of an assistive technology for learning through psychophysiological evaluations in elementary school children
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN51750695·No longer recruiting·Salmonella vaccine study in Oxford
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Histidinemia — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Histidinemia" OR "HAL deficiency" OR "HIS deficiency" OR "Histidase deficiency" OR "Histidine ammonia-lyase deficiency" OR "Histidinuria" OR "Hyperhistidinemia") OR ("HAL syndrome" OR "HAL-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Histidinemia" OR "HAL deficiency" OR "HIS deficiency" OR "Histidase deficiency" OR "Histidine ammonia-lyase deficiency" OR "Histidinuria" OR "Hyperhistidinemia"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T19:19:27.095Z
